Evidence map›Paper›PMID 27129877›Full record

ArticleStem cell research & therapy2016

The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo.

Shuling Hu, Jinze Li, Xiuping Xu, Airan Liu, Hongli He, Jingyuan Xu, Qihong Chen, Songqiao Liu, Ling Liu, Haibo Qiu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shuling HuDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Jinze LiDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Xiuping XuDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Airan LiuDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Hongli HeDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Jingyuan XuDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Qihong ChenDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Songqiao LiuDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Ling LiuDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Haibo QiuDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China.
Yi YangDepartment of Critical Care Medicine, Zhongda Hospital, Southeast University School of Medicine, No.87 Dingjiaqiao Road, Nanjing, 210009, Jiansu, P.R. China. yiyiyang2004@163.com.
Zhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute respiratory distress syndrome (ARDS) is a life-threatening condition in critically ill patients. Recently, we have found that mesenchymal stem cells (MSC) improved the permeability of human lung microvascular endothelial cells by secreting hepatocyte growth factor (HGF) in vitro. However, the properties and functions of MSC may change under complex circumstances in vivo. Here, we sought to determine the role of the HGF-expressing character of MSC in the therapeutic effects of MSC on ARDS in vivo.

methodsMSC with HGF gene knockdown (MSC-ShHGF) were constructed using lentiviral transduction. The HGF mRNA and protein levels in MSC-ShHGF were detected using quantitative real-time polymerase chain reaction and Western blotting analysis, respectively. HGF levels in the MSC culture medium were measured by enzyme-linked immunosorbent assay (ELISA). Rats with ARDS induced by lipopolysaccharide received MSC infusion via the tail vein. After 1, 6, and 24 h, rats were sacrificed. MSC retention in the lung was assessed by immunohistochemical assay. The lung wet weight to body weight ratio (LWW/BW) and Evans blue dye extravasation were obtained to reflect lung permeability. The VE-cadherin was detected with inmmunofluorescence, and the lung endothelial cell apoptosis was assessed by TUNEL assay. The severity of lung injury was evaluated using histopathology. The cytokines and HGF levels in the lung were measured by ELISA.

resultsMSC-ShHGF with markedly lower HGF expression were successfully constructed. Treatment with MSC or MSC carrying green fluorescent protein (MSC-GFP) maintained HGF expression at relatively high levels in the lung at 24 h. MSC or MSC-GFP decreased the LWW/BW and the Evans Blue Dye extravasation, protected adherens junction VE-cadherin, and reduced the lung endothelial cell apoptosis. Furthermore, MSC or MSC-GFP reduced the inflammation and alleviated lung injury based on histopathology. However, HGF gene knockdown significantly decreased the HGF levels without any changes in the MSC retention in the lung, and diminished the protective effects of MSC on the injured lung, indicating the therapeutic effects of MSC on ARDS were partly associated with the HGF-expressing character of MSC.

conclusionsMSC restores lung permeability and lung injury in part by maintaining HGF levels in the lung and the HGF-expressing character is required for MSC to protect the injured lung.

Indexed as

Mesenchymal Stem Cell TransplantationAcute Lung InjuryAnimalsApoptosisBody WeightCadherinsCapillary PermeabilityGene Expression RegulationGenes, ReporterGreen Fluorescent ProteinsHepatocyte Growth FactorHumansLentivirusLipopolysaccharidesLungMaleCadherinsCDH1 protein, ratGreen Fluorescent ProteinsHepatocyte Growth FactorLipopolysaccharidesRNA, MessengerRNA, Small InterferingAcute lung injuryHepatic growth factorLung vascular permeabilityMesenchymal stem cell

Identifiers

PMID27129877
PMCPMC4850641
OpenAlexW2342448667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.